心力衰竭患者SGLT2抑制剂治疗中水潴留抵消渗透性利尿
DAPA-Shuttle1随机双盲安慰剂对照试验纳入慢性心衰NYHA I/II级且射血分数降低患者,达格列净10 mg每日一次治疗4周。结果显示达格列净增加尿糖排泄,但血清和肽素升高导致自由水清除率下降、尿液浓缩,尿量未显著增加,提示生理性水潴留抵消了渗透性利尿效应。
要点
- 达格列净早期和晚期均增加尿糖排泄,但尿量无显著增加。
- 达格列净升高血清和肽素,降低自由水清除率并提高尿渗透压。
- 心衰患者使用达格列净时渗透性利尿作用被水潴留机制抵消。
核心结论
- 生理适应性水潴留消除了达格列净预期的渗透性利尿潜力,防止了葡萄糖驱动的尿量增加约10 mL/kg/d·75 kg=750 mL/kg/d。
研究设计与样本
- DAPA-Shuttle1为单中心、双盲、随机、安慰剂对照试验,慢性心衰NYHA I/II级且射血分数降低患者随机接受达格列净10 mg每日一次或安慰剂(1:1)治疗4周。
主要发现
- 达格列净治疗48小时内(早期)尿糖排泄孤立性增加3.3 mmol/kg/d(95%CI:2.51-4.04;P<0.0001),4周后(晚期)持续增加2.7 mmol/kg/d(95%CI:1.98-3.51;P<0.0001)。
- 达格列净治疗早期升高血清和肽素5.5 pmol/L(95%CI:0.45-10.5;P<0.05),晚期升高7.8 pmol/L(95%CI:2.77-12.81;P<0.01)。
- 达格列净治疗早期自由水清除率降低9.1 mL/kg/d(95%CI:-14至-4.12;P<0.001),晚期降低11.0 mL/kg/d(95%CI:-15.94至-6.07;P<0.0001),晚期尿渗透压升高134 mmol/L(95%CI:39.28-229.12;P<0.01)。
- 达格列净治疗尿量无显著增加:早期平均差异2.8 mL/kg/d(95%CI:-1.97至7.48;P=0.25),晚期平均差异0.9 mL/kg/d(95%CI:-3.83至5.62;P=0.70)。
临床怎么用
- 心衰患者使用达格列净时,不应期望通过渗透性利尿增加尿量来改善容量状态。
- 达格列净的临床获益可能不完全依赖于其利尿效应,需关注水潴留机制的影响。
局限性
- 研究样本量较小(29例提供准确尿液收集),可能影响结果的普遍性。
- 研究为单中心设计,随访时间4周,长期效应未评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sodium-glucose cotransporter 2 inhibitors are believed to improve cardiac outcomes due to their osmotic diuretic potential. OBJECTIVES: The goal of this study was to test the hypothesis that vasopressin-driven urine concentration overrides the osmotic diuretic effect of glucosuria induced by dapagliflozin treatment. METHODS: DAPA-Shuttle1 (Hepato-renal Regulation of Water Conservation in Heart Failure Patients With SGLT-2 Inhibitor Treatment) was a single-center, double-blind, randomized, placebo-controlled trial, in which patients with chronic heart failure NYHA functional classes I/II and reduced ejection fraction were randomly assigned to receive dapagliflozin 10 mg daily or placebo (1:1) for 4 weeks. The primary endpoint was change from baseline in urine osmolyte concentration. Secondary endpoints included changes in copeptin levels and solute free water clearance. RESULTS: Thirty-three randomized, sodium-glucose cotransporter 2 inhibitor-naïve participants completed the study, 29 of whom (placebo: n = 14; dapagliflozin: n = 15) provided accurate 24-hour urine collections (mean age 59 ± 14 years; left ventricular ejection fraction 31% ± 9%). Dapagliflozin treatment led to an isolated increase in urine glucose excretion by 3.3 mmol/kg/d (95% CI: 2.51-4.04; P < 0.0001) within 48 hours (early) which persisted after 4 weeks (late; 2.7 mmol/kg/d [95% CI: 1.98-3.51]; P < 0.0001). Dapagliflozin treatment increased serum copeptin early (5.5 pmol/L [95% CI: 0.45-10.5]; P < 0.05) and late (7.8 pmol/L [95% CI: 2.77-12.81]; P < 0.01), leading to proportional reductions in free water clearance (early: -9.1 mL/kg/d [95% CI: -14 to -4.12; P < 0.001]; late: -11.0 mL/kg/d [95% CI: -15.94 to -6.07; P < 0.0001]) and elevated urine concentrations (late: 134 mmol/L [95% CI: 39.28-229.12]; P < 0.01). Therefore, urine volume did not significantly increase with dapagliflozin (mean difference early: 2.8 mL/kg/d [95% CI: -1.97 to 7.48; P = 0.25]; mean difference late: 0.9 mL/kg/d [95% CI: -3.83 to 5.62]; P = 0.70). CONCLUSIONS: Physiological-adaptive water conservation eliminated the expected osmotic diuretic potential of dapagliflozin and thereby prevented a glucose-driven increase in urine volume of approximately 10 mL/kg/d · 75 kg = 750 mL/kg/d. (Hepato-renal Regulation of Water Conservation in Heart Failure Patients With SGLT-2 Inhibitor Treatment [DAPA-Shuttle1]; NCT04080518).
引用
- Marton, Saffari, Rauh, et al. Water Conservation Overrides Osmotic Diuresis During SGLT2 Inhibition in Patients With Heart Failure. J Am Coll Cardiol. 2024. PMID: 38599715. doi:10.1016/j.jacc.2024.02.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。